{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:08:26Z","timestamp":1788779306355,"version":"build-2803163510"},"reference-count":37,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Systemic treatment of cutaneous melanoma has changed since 2011, with clinical studies demonstrating improved outcomes. This analysis evaluated whether this improvement is evident in a real\u2010world cohort, focusing on overall survival (OS) and relapse\u2010free survival (RFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>10,270 patients with cutaneous melanoma were analyzed. Kaplan\u2010Meier analyses for OS and RFS were used to compare 4,846 patients diagnosed in 2001\u20132010 with 5,424 patients diagnosed in 2011\u20132020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Regarding OS, differences were found for stages II\u2013IV. 5\u2010year OS was 78.2% and 85.2% in stage\u00a0II, 56.5% and 70.7% in stage\u00a0III, and 9.8% and 34.6% in stage\u00a0IV. However, in stage\u00a0I no difference was observed between the two periods, with 5\u2010year OS of 95.9% and 96.2%. For RFS, no differences were observed in stages I\u2013III, with 5\u2010year RFS of 93.6% and 93.1% in stage\u00a0I, 66.9% and 64.3% in stage\u00a0II, and 38.2% and 42.5% in stage\u00a0III.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>OS has improved in stages II\u2013IV. The difference in stage\u00a0II may be caused by the high number of patients progressing to stages III\u2013IV. No differences were found for RFS in any stage. Since adjuvant therapies were approved starting in 2018, it is still too early to observe an effect.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ddg.70470","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:12:53Z","timestamp":1788775973000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Improvement of overall survival in patients with cutaneous melanoma at a tertiary care center in Germany from 2001 to 2020"],"prefix":"10.1111","author":[{"given":"Lena","family":"Nanz","sequence":"first","affiliation":[{"name":"Center for Dermatooncology Department of Dermatology University of T\u00fcbingen  T\u00fcbingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[{"name":"Center for Dermatooncology Department of Dermatology University of T\u00fcbingen  T\u00fcbingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7134-1043","authenticated-orcid":false,"given":"Markus","family":"Reitmajer","sequence":"additional","affiliation":[{"name":"Center for Dermatooncology Department of Dermatology University of T\u00fcbingen  T\u00fcbingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6185-4945","authenticated-orcid":false,"given":"Andrea","family":"Forschner","sequence":"additional","affiliation":[{"name":"Center for Dermatooncology Department of Dermatology University of T\u00fcbingen  T\u00fcbingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Maczey\u2010Leber","sequence":"additional","affiliation":[{"name":"Center for Dermatooncology Department of Dermatology University of T\u00fcbingen  T\u00fcbingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Amaral","sequence":"additional","affiliation":[{"name":"Center for Dermatooncology Department of Dermatology University of T\u00fcbingen  T\u00fcbingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Flatz","sequence":"additional","affiliation":[{"name":"Center for Dermatooncology Department of Dermatology University of T\u00fcbingen  T\u00fcbingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8019-1577","authenticated-orcid":false,"given":"Ulrike","family":"Leiter","sequence":"additional","affiliation":[{"name":"Center for Dermatooncology Department of Dermatology University of T\u00fcbingen  T\u00fcbingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/jdv.12236","article-title":"Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015","volume":"28","author":"Arnold M","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/jdv.15322","article-title":"Time trends in incidence and mortality of cutaneous melanoma in Germany","volume":"33","author":"Garbe C","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2021.04.029","article-title":"Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943\u20102036","volume":"152","author":"Garbe C","year":"2021","journal-title":"Eur J Cancer"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-3-030-46227-7_6","article-title":"Epidemiology of skin cancer: Update 2019","volume":"1268","author":"Leiter U","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.45269","article-title":"Melanoma treatments and mortality rate trends in the US, 1975 to 2019","volume":"5","author":"Kahlon N","year":"2022","journal-title":"JAMA Netw Open"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejca.2023.03.019","article-title":"Survival in melanoma in the nordic countries into the era of targeted and immunological therapies","volume":"186","author":"Tichanek F","year":"2023","journal-title":"Eur J Cancer"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5694\/mja2.52404","article-title":"Changes in the incidence of melanoma in Australia, 2006\u20102021, by age group and ancestry: A modelling study","volume":"221","author":"Whiteman DC","year":"2024","journal-title":"Med J Aust"},{"key":"e_1_2_8_9_1","first-page":"472","article-title":"Melanoma staging: Evidence\u2010based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald JE","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2019.06.011","article-title":"Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma","volume":"119","author":"Kanaki T","year":"2019","journal-title":"Eur J Cancer"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2017.11.023","article-title":"Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III","volume":"91","author":"Grob JJ","year":"2018","journal-title":"Eur J Cancer"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow\u2010up","volume":"36","author":"Amaral T","year":"2025","journal-title":"Ann Oncol"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf D","year":"2018","journal-title":"Lancet"},{"key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2020.02.021","article-title":"Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition \u2010 Update 2019","volume":"130","author":"Ugurel S","year":"2020","journal-title":"Eur J Cancer"},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","article-title":"Cutaneous melanoma","volume":"402","author":"Long GV","year":"2023","journal-title":"Lancet"},{"key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00432-023-05533-0","article-title":"Long\u2010term survival of stage IV melanoma patients: Evaluation on 640 melanoma patients entering stage IV between 2014 and 2017","volume":"150","author":"Reitmajer M","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.26641","article-title":"Long\u2010term survival in patients with advanced melanoma","volume":"7","author":"Not OJ","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ddg.12113_suppl","article-title":"Malignant melanoma S3\u2010guideline \"diagnosis, therapy and follow\u2010up of melanoma\"","volume":"11","author":"Pflugfelder A","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.clindermatol.2012.08.016","article-title":"Chemotherapy in the management of advanced cutaneous malignant melanoma","volume":"31","author":"Luke JJ","year":"2013","journal-title":"Clin Dermatol"},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: Optimizing outcomes in melanoma","volume":"14","author":"Luke JJ","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2015.09.013","article-title":"Survival of patients with advanced metastatic melanoma: The impact of novel therapies","volume":"53","author":"Ugurel S","year":"2016","journal-title":"Eur J Cancer"},{"key":"e_1_2_8_22_1","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-21-0809","article-title":"5\u2010Year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation\u2010positive advanced melanoma: Extended follow\u2010up of the coBRIM study","volume":"27","author":"Ascierto PA","year":"2021","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_23_1","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five\u2010year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert C","year":"2019","journal-title":"N Engl J Med"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1200\/JCO.21.02659","article-title":"COLUMBUS 5\u2010year update: A randomized, open\u2010label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600\u2010mutant melanoma","volume":"40","author":"Dummer R","year":"2022","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_25_1","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1200\/JCO.20.00995","article-title":"Five\u2010year outcomes with nivolumab in patients with wild\u2010type BRAF advanced melanoma","volume":"38","author":"Robert C","year":"2020","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE\u2010006): Post\u2010hoc 5\u2010year results from an open\u2010label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert C","year":"2019","journal-title":"Lancet Oncol"},{"key":"e_1_2_8_27_1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five\u2010Year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin J","year":"2019","journal-title":"N Engl J Med"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10\u2010year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok JD","year":"2025","journal-title":"N Engl J Med"},{"key":"e_1_2_8_29_1","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ejso.2019.01.225","article-title":"Stage\u2010specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma","volume":"45","author":"Leeneman B","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"e_1_2_8_30_1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2021.06.007","article-title":"Stage\u2010specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003\u20132018): A nationwide population\u2010based study","volume":"154","author":"Leeneman B","year":"2021","journal-title":"Eur J Cancer"},{"key":"e_1_2_8_31_1","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamadermatol.2023.3256","article-title":"Stage\u2010specific risk of recurrence and death from melanoma in Denmark, 2008\u20132021: A national observational cohort study of 25\u00a0720 patients with stage IA to IV melanoma","volume":"159","author":"Helvind NM","year":"2023","journal-title":"JAMA Dermatol"},{"key":"e_1_2_8_32_1","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/bjd\/ljad244","article-title":"Increasing melanoma incidence and survival trend shifts with improved melanoma\u2010specific survival between 1990 and 2020 in Sweden","volume":"189","author":"Vikstr\u00f6m S","year":"2023","journal-title":"Br J Dermatol"},{"key":"e_1_2_8_33_1","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE\u2010716): A randomised, double\u2010blind, phase 3 trial","volume":"399","author":"Luke JJ","year":"2022","journal-title":"Lancet"},{"key":"e_1_2_8_34_1","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: Primary results from the randomized, phase 3 CheckMate 76K trial","volume":"29","author":"Kirkwood JM","year":"2023","journal-title":"Nat Med"},{"key":"e_1_2_8_35_1","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont AMM","year":"2018","journal-title":"N Engl J Med"},{"key":"e_1_2_8_36_1","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber J","year":"2017","journal-title":"N Engl J Med"},{"key":"e_1_2_8_37_1","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF\u2010mutated melanoma","volume":"377","author":"Long GV","year":"2017","journal-title":"N Engl J Med"},{"key":"e_1_2_8_38_1","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1200\/JCO.2003.01.091","article-title":"Prospective evaluation of a follow\u2010up schedule in cutaneous melanoma patients: Recommendations for an effective follow\u2010up strategy","volume":"21","author":"Garbe C","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.70470","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ddg.70470","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.70470","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:12:58Z","timestamp":1788775978000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.70470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":37,"alternative-id":["10.1111\/ddg.70470"],"URL":"https:\/\/doi.org\/10.1111\/ddg.70470","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"2025-10-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ddg.70470"}}